182 related articles for article (PubMed ID: 16309845)
1. Kinetic analysis of the inhibition of human butyrylcholinesterase with cymserine.
Kamal MA; Al-Jafari AA; Yu QS; Greig NH
Biochim Biophys Acta; 2006 Feb; 1760(2):200-6. PubMed ID: 16309845
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine.
Kamal MA; Klein P; Luo W; Li Y; Holloway HW; Tweedie D; Greig NH
Neurochem Res; 2008 May; 33(5):745-53. PubMed ID: 17985237
[TBL] [Abstract][Full Text] [Related]
3. Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine.
Kamal MA; Klein P; Yu QS; Tweedie D; Li Y; Holloway HW; Greig NH
J Alzheimers Dis; 2006 Sep; 10(1):43-51. PubMed ID: 16988481
[TBL] [Abstract][Full Text] [Related]
4. Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis.
Kamal MA; Qu X; Yu QS; Tweedie D; Holloway HW; Li Y; Tan Y; Greig NH
J Neural Transm (Vienna); 2008 Jun; 115(6):889-98. PubMed ID: 18235987
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Butyrylcholinesterase with Fluorobenzylcymserine, An Experimental Alzheimer's Drug Candidate: Validation of Enzoinformatics Results by Classical and Innovative Enzyme Kinetic Analyses.
Kamal MA; Shakil S; Nawaz MS; Yu QS; Tweedie D; Tan Y; Qu X; Greig NH
CNS Neurol Disord Drug Targets; 2017; 16(7):820-827. PubMed ID: 28176640
[TBL] [Abstract][Full Text] [Related]
6. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase.
Greig NH; Utsuki T; Yu Q; Zhu X; Holloway HW; Perry T; Lee B; Ingram DK; Lahiri DK
Curr Med Res Opin; 2001; 17(3):159-65. PubMed ID: 11900310
[TBL] [Abstract][Full Text] [Related]
7. Molecular interaction study of N1-p-fluorobenzyl-cymserine with TNF-α , p38 kinase and JNK kinase.
Batool S; Nawaz MS; Greig NH; Rehan M; Kamal MA
Antiinflamm Antiallergy Agents Med Chem; 2013; 12(2):129-35. PubMed ID: 23360257
[TBL] [Abstract][Full Text] [Related]
8. Targeting acetylcholinesterase and butyrylcholinesterase in dementia.
Lane RM; Potkin SG; Enz A
Int J Neuropsychopharmacol; 2006 Feb; 9(1):101-24. PubMed ID: 16083515
[TBL] [Abstract][Full Text] [Related]
9. Cholinesterases: new roles in brain function and in Alzheimer's disease.
Giacobini E
Neurochem Res; 2003 Apr; 28(3-4):515-22. PubMed ID: 12675140
[TBL] [Abstract][Full Text] [Related]
10. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy.
Greig NH; Lahiri DK; Sambamurti K
Int Psychogeriatr; 2002; 14 Suppl 1():77-91. PubMed ID: 12636181
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease.
Yu Q; Holloway HW; Utsuki T; Brossi A; Greig NH
J Med Chem; 1999 May; 42(10):1855-61. PubMed ID: 10346939
[TBL] [Abstract][Full Text] [Related]
12. In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses.
Kuhl DE; Koeppe RA; Snyder SE; Minoshima S; Frey KA; Kilbourn MR
Ann Neurol; 2006 Jan; 59(1):13-20. PubMed ID: 16278840
[TBL] [Abstract][Full Text] [Related]
13. Kinetics of human acetylcholinesterase inhibition by the novel experimental Alzheimer therapeutic agent, tolserine.
Kamal MA; Greig NH; Alhomida AS; Al-Jafari AA
Biochem Pharmacol; 2000 Aug; 60(4):561-70. PubMed ID: 10874131
[TBL] [Abstract][Full Text] [Related]
14. The interactions of azure B, a metabolite of methylene blue, with acetylcholinesterase and butyrylcholinesterase.
Petzer A; Harvey BH; Petzer JP
Toxicol Appl Pharmacol; 2014 Feb; 274(3):488-93. PubMed ID: 24161345
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease?
Giacobini E
Drugs Aging; 2001; 18(12):891-8. PubMed ID: 11888344
[TBL] [Abstract][Full Text] [Related]
16. Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons.
Darvesh S; Arora RC; Martin E; Magee D; Hopkins DA; Armour JA
Exp Neurol; 2004 Aug; 188(2):461-70. PubMed ID: 15246845
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of human cholinesterases by drugs used to treat Alzheimer disease.
Darvesh S; Walsh R; Kumar R; Caines A; Roberts S; Magee D; Rockwood K; Martin E
Alzheimer Dis Assoc Disord; 2003; 17(2):117-26. PubMed ID: 12794390
[TBL] [Abstract][Full Text] [Related]
18. Species- and concentration-dependent differences of acetyl- and butyrylcholinesterase sensitivity to physostigmine and neostigmine.
Bitzinger DI; Gruber M; Tümmler S; Michels B; Bundscherer A; Hopf S; Trabold B; Graf BM; Zausig YA
Neuropharmacology; 2016 Oct; 109():1-6. PubMed ID: 26772968
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of phenserine analogues and evaluation of their cholinesterase inhibitory activities.
Shinada M; Narumi F; Osada Y; Matsumoto K; Yoshida T; Higuchi K; Kawasaki T; Tanaka H; Satoh M
Bioorg Med Chem; 2012 Aug; 20(16):4901-14. PubMed ID: 22831800
[TBL] [Abstract][Full Text] [Related]
20. Cholinesterase inhibitors: new roles and therapeutic alternatives.
Giacobini E
Pharmacol Res; 2004 Oct; 50(4):433-40. PubMed ID: 15304240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
